WuXi Biologics (Cayman)
$54.00Change from previous close: −3.66%Absolute change: −$2.05
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $222.28B
- Enterprise value
- $226.3B
- P/E (trailing 12 months)
- 38.8
- Forward P/E
- 24.9
- PEG
- 0.75
- Price/book
- 3.94
- Price/sales
- 9.41
- EV/EBITDA
- 25.1
- EV/revenue
- 9.58
Profitability and growth
- Gross margin
- 47.5%
- Operating margin
- 31.6%
- Net margin
- 21.2%
- ROE
- 11.4%
- ROA
- 7.6%
- Revenue growth (year over year)
- 18.4%
- Earnings growth (year over year)
- 4.3%
Financial health
- Total cash
- $13.03B
- Total debt
- $2.73B
- Debt/equity
- 0.05
- Current ratio
- 3.32
- Quick ratio
- 2.64
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $58.10
- Median price target
- $60.10
- High price target
- $79.18
- Low price target
- $30.88
- Analysts with a price target
- 24
- Consensus
- Buy
- Forward EPS
- $2.17
- EPS estimate, current year
- $1.55
Shares and trading
- Beta
- 0.62
- Average volume
- 35.39M
- Shares outstanding
- 4.12B
- Float
- 3.71B
- Institutional ownership
- 36.3%
- Insider ownership
- 10.1%